MedTrace Logo

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

NCT03232255 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-01-03

No results posted yet for this study

Summary

This study is to evaluate the benefit and tolerability of a Mouthrinse (IQP-OLP-101) in the treatment of dentine hypersensitivity.

Conditions

  • Dentin Sensitivity

Interventions

OTHER

Mouthrinse (IQP-OLP-101)

Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-25
Primary Completion
2017-12-07
Completion
2017-12-07

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232255 on ClinicalTrials.gov